Citation

Yılmaz N, Yelboga Z, Yilmaz Y, Demirpence O. J. Med. Biochem. 2021; 40(3): 295-301.

Copyright

(Copyright © 2021, Walter de Gruyter)

DOI

10.5937/jomb0-28108

PMID

unavailable

Abstract

BACKGROUND: Schizophrenia is a chronic mental disorder, characterized byacute exacerbation and remission phases.Immune system has a role in the pathophysiology of schizophrenia. High mobility group box-1 (HMGB-1) is a macrophage secreted protein activating immune cells to produce cytokines. The aim of this study was to evaluate HMGB-1 levels among patients with schizophrenia both in acute exacerbation and remission phases.

METHODS: Consecutive schizophrenia patients in acute exacerbation and remission phases were enrolled and compared with each other and with age-sex matched healthy subjects. Patients were assessed with the Scale for the Assessment of Positive Symptoms (SAPS), Scale for the Assessment of Negative Symptoms (SANS), Brief Psychiatric Rating Scale (BPRS), Clinical Global Impression Scale (CGI).

RESULTS: Mean HMGB-1 levels were not significantly different in acute exacerbation phase versus remission phase schizophrenia patients (2.139±0.564 μg/L vs. 2.326± 0.471 μg/L, p=0.335) and both were individually higher than the control group (1.791±0.444 μg/L, p=0.05 for acute exacerbation vs control, p=0.002 for remission vs control). In remission phase schizophrenic patients, HMGB-1 levels were positively correlated with Scale For The Assessment of Positive Symptoms (r=0.447, p=0.015) and BPRS (r=0.397, p=0.033) scores and HMGB-1 levels were independently associated with BPRS.

CONCLUSIONS: Serum HMGB-1 levels were shown to be increased in patients with schizophrenia patients irrespective of phase, there were no differences between patients in acute exacerbation and remission phase in terms of biomarker and HMGB-1 levels were related to symptom severity according to psychiatric scales among patients in remission phase of schizophrenia. © 2021 Sciendo. All rights reserved.

Language: en

Keywords

adult; human; age; female; male; Schizophrenia; schizophrenia; suicide attempt; hospitalization; Brief Psychiatric Rating Scale; comparative study; controlled study; neuroleptic agent; blood sampling; clinical article; human cell; human tissue; psychopharmacotherapy; cross-sectional study; disease exacerbation; outpatient department; atypical antipsychotic agent; positive syndrome; protein blood level; remission; disease duration; mood stabilizer; Article; biological marker; Clinical Global Impression scale; enzyme linked immunosorbent assay; high mobility group B1 protein; Scale for the Assessment of Negative Symptoms; HMGB-1; Remission and acute exacerbation phase; Scale for the Assessment of Positive Symptoms Scale; schizophrenia assessment